Oral Mucositis Adjunct Treatment for Cancer Patients 'MucosaMin' Obtains Medical Device Certification from MFDS

BigThink Therapeutics, the bio-subsidiary of KPS, announced on the 5th that it has obtained medical device product certification for MUCOSAMIN®, a topical solution for managing oral mucositis in cancer patients. With this, full-scale sales will begin in the second half of the year, accelerating not only the domestic pharmaceutical market but also overseas licensing agreements.

According to the company, BigThink secured the Asian rights for MUCOSAMIN (including Korea, Japan, Malaysia, Hong Kong, Singapore, Taiwan, Indonesia, the Philippines, Vietnam, etc.) in December 2020, and signed its first overseas contract with Taiwanese pharmaceutical company CHIFU in January last year. Subsequently, it obtained certification as a Class 2 medical device through the review of the Korea Medical Device Safety Information Center under the Ministry of Food and Drug Safety, allowing exclusive sales in Korea.

MUCOSAMIN is an oral liquid formulation that helps prevent and treat oral mucositis caused by anticancer treatments such as radiation and chemotherapy, and also shows efficacy in dry mouth. This medical device was developed by the Italian amino acid specialist pharmaceutical company Professional Dietetics S.p.A. (PD) and is approved and sold in the European Union (EU), as well as the UK, Canada, Switzerland, Israel, Jordan, Morocco, Iran, India, Nepal, and other countries.

MUCOSAMIN, in the form of a viscous liquid gel, acts as a wound dressing by forming a physical barrier when applied to the oral mucosa or surgical wounds, protecting the wound from external environments. It also reduces pain and promotes the maintenance and recovery of normal physiological conditions.

Kim Ha-yong, CEO of BigThink, said, "It is encouraging to provide a new treatment option for cancer patients suffering from oral symptoms," adding, "Following last year’s licensing agreement with CHIFU and securing domestic product certification, we will accelerate BigThink’s globalization." He emphasized, "Since the sales of our first pharmaceutical product, the breast cancer drug Neorings tablet, reached 3 billion KRW in the first half of this year (January to June), we will strive to surpass 10 billion KRW in annual sales."

BigThink plans to collaborate with domestic pharmaceutical companies to launch MUCOSAMIN while continuing to expand its anticancer drug portfolio, solidifying its position as a specialized anticancer pharmaceutical company.

This content was produced with the assistance of AI translation services.